Background: Lung cancer patients with mutations in the epithelial growth factor receptor (EGFR) are treated with tyrosine kinase inhibitors (TKI) such as Erlotinib. Although resistance to EGFR-TKI is common, it is not known how biomechanical factors in the lung tumor microenvironment alters resistance. Alveolar epithelial cells experience 15% cyclic strain while increased tumor stiffness result in 40-fold decrease in cyclic strain. However, it is not known if cyclic mechanical strain alters the sensitivity of lung adenocarcinoma cells to EGFR-TKI. Mechanical stretch and silencing a membrane repair protein, myoferlin (MYOF), results in fluidization of the actin cytoskeleton. In this study we investigated how cyclic strain and silencing MYOF modulates EGFR expression and Erlotinib sensitivity in lung adenocarcinoma cells. Method: A Flexcell system was used expose human lung adenocarcinoma cells (A549 and H1299) to 0.2Hz cyclic strain (0-15%) for 72h. To knockdown MYOF expression, cells were treated with 30uM siRNA for 24h. Cells were expose to a range of Eroltinib concentrations and a MTT cell proliferation assay was used to determine the concentration require to reduce proliferation by 50% (i.e. IC50). Western blots and immunohistochemistry were used to quantify EGFR expression and localization. Result: Increasing the magnitude of cyclic strain caused a dramatic decrease in IC50 for A549 and H1299 cells. Similarly, silencing MYOF lead to a dramatic decrease in IC50 in A549 and H1299 cells. Cyclic strain and MYOF knockdown resulted in both increased EGFR expression and internalization. Conclusion: Low levels of cyclic strain in the lung tumor microenvironment lead to increased Erlotinib resistance and exposure to physiologic levels of cyclic strain initiates EGFR signaling and increases Erlotinib sensitivity. This highlights the need for modeling and characterizing the mechanics of the lung tumor microenvironment to investigate how cyclic strain and MYOF expression influence chemosensitivity to other cancer therapeutics.
Background: Lung cancer patients with mutations in the epithelial growth factor receptor (EGFR) are treated with tyrosine kinase inhibitors (TKI) such as Erlotinib. Although resistance to EGFR-TKI is common, it is not known how biomechanical factors in the lung tumor microenvironment alters resistance. Alveolar epithelial cells experience 15% cyclic strain while increased tumor stiffness result in 40-fold decrease in cyclic strain. However, it is not known if cyclic mechanical strain alters the sensitivity of lung adenocarcinoma cells to EGFR-TKI. Mechanical stretch and silencing a membrane repair protein, myoferlin (MYOF), results in fluidization of the actin cytoskeleton. In this study we investigated how cyclic strain and silencing MYOF modulates EGFR expression and Erlotinib sensitivity in lung adenocarcinoma cells. Method: A Flexcell system was used expose human lung adenocarcinoma cells (A549 and H1299) to 0.2Hz cyclic strain (0-15%) for 72h. To knockdown MYOF expression, cells were treated with 30uM siRNA for 24h. Cells were expose to a range of Eroltinib concentrations and a MTT cell proliferation assay was used to determine the concentration require to reduce proliferation by 50% (i.e. IC50). Western blots and immunohistochemistry were used to quantify EGFR expression and localization. Result: Increasing the magnitude of cyclic strain caused a dramatic decrease in IC50 for A549 and H1299 cells. Similarly, silencing MYOF lead to a dramatic decrease in IC50 in A549 and H1299 cells. Cyclic strain and MYOF knockdown resulted in both increased EGFR expression and internalization. Conclusion: Low levels of cyclic strain in the lung tumor microenvironment lead to increased Erlotinib resistance and exposure to physiologic levels of cyclic strain initiates EGFR signaling and increases Erlotinib sensitivity. This highlights the need for modeling and characterizing the mechanics of the lung tumor microenvironment to investigate how cyclic strain and MYOF expression influence chemosensitivity to other cancer therapeutics. Keywords: NSCLC, drug resistance, tumor microenvironment. Epidermal Growth Factor Receptor (EGFR) mutation predicts response to a tyrosine kinase inhibitor (TKI) of EGFR in approximately 25% of patients. All ANSCLC patients with EGFR mutation eventually develop resistance to EGFR-TKI. The mechanism of resistance is not fully elucidated but majority of the cases is related to emergence of clones with T790M mutation in EGFR, and amplification of MET. Recently, increasing numbers of miRNAs, non-coding RNAs are correlated with the drug resistance indicating that miRNAs may serve as novel targets and/or promising predictive biomarkers for anti-EGFR therapy. In this study, we investigated the role of miRNA-506 in the regulation of Sonic Hedgehog (SHh) in TKI-resistant lung cancer cell lines. Method: To generate cell lines resistant to EGFR TKI, HCC4006 cells were exposed to increasing concentrations of erlotinib over 6 months with increasing concentration upto 20 mM. The resultant clones (designated HCC4006 ER1 to HCC4006 ER4), following expansion from single cell. Cell viability was measured by crystal violet staining assay. The expression of miRNA in parental and resistant clones was checked by real-time qRT-PCR. The mRNA and protein expression level of SHh was determined by real-time qRT-PCR and Western blot. Invasive/migratory ability of parental and resistant clones was measured by Boyden chamber assays. EMT and stemness markers were evaluated by Western blot. Single-cell suspensions from pre-treated cells were resuspended at a density of 500 cells/ml mammocult media in ultralow attachment dishes. Number as well as the size of the tumorosphere/ spheroids in specified experimental set-up was monitored and recorded alternate day for 8-10 days. Result: The studies demonstrated that miR-506 was downregulated in resistant clone as compared to parental cell lines which promotes significantly the invasive/migratory ability and EMT phenotypes of lung cancer cells through induction of SHh. Interestingly, ectopic expression of miRNA-506 in these resistant cells inhibits SHh signaling and thus reprograms EMT, EGFR-TKI resistance and stemness. Conclusion: Our data suggest that miR-506 downregulation and induction of SHh are associated with resistance to EGFR-TKI. miR-506 interference and inhibition of SHh pathway are potential therapeutic strategy to reverse resistance to EGFR-TKI in NSCLC with EGFR mutation. (FOXM1) is a member of the forkhead superfamily of transcription factors. It plays numerous critical roles in cancer development and progression, such as the regulation of G2/M transitions of cell cycle, anti-apoptosis, DNA damage repair, invasion, and drug resistance. In a pan-cancer meta-analysis of mRNA expression signatures from w18,000 human tumors with overall survival outcomes across 39 malignancies, over expression of the FOXM1 was a major predictor of adverse outcomes and appeared anti-correlated with tumor immune cell populations (Nat Med. 2015; 21(8) :938-945). Thus, we examined the prognostic and biological role of FOXM1 in non-small cell lung cancer (NSCLC). Method: We examined the prognostic impact of FOXM1 expression in lung cancer patients using a genomic database (UTSW e "Lung Cancer Explorer" and KM-Plotter). We also assessed the expression of FOXM1 in NSCLC lines, and human bronchial epithelial cells (HBECs), and assessed the association between FOXM1 and cell cycle related genes in RNA-seq data. We examined the effect of the downregulation of FOXM1 on tumor
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